Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

著者: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Tanja Badovinac-Črnjević, Silke Hoersch, Melanie C. Smitt, Hans Wildiers - The Lancet 2017 被引用: 523